v.231201
Showing details for project SYSMHC00007
| SampleID |
NumReplicates |
Organism |
TissueType |
CellType |
MHCAllele |
| SampleID |
NumReplicates |
Organism |
TissueType |
CellType |
MHCAllele |
| SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229 |
3 |
Human |
|
|
HLA-A03:01,HLA-B35:01,HLA-C04:01 |
| SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D |
3 |
Human |
|
|
HLA-A03:01,HLA-B35:01,HLA-C04:01 |
| SYSMHC00007_shraibmanb_160819_admon_Israel_T98G |
3 |
Human |
|
|
HLA-A02:01,HLA-B39:06,HLA-C07:02 |
| SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD |
3 |
Human |
|
|
HLA-A02:01,HLA-B39:06,HLA-C07:02 |
| SYSMHC00007_shraibmanb_160819_admon_Israel_U87 |
3 |
Human |
|
|
HLA-A02:01,HLA-B44:02,HLA-C05:01 |
| SYSMHC00007_shraibmanb_160819_admon_Israel_U87D |
3 |
Human |
|
|
HLA-A02:01,HLA-B44:02,HLA-C05:01 |
Detailed view of sample SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D
| ID |
SampleID |
RawFileName |
Organism |
Process |
Tissue Type |
Cell Type |
Culture Conditions |
Disease State |
Comments |
MHCClass |
MHCAllele |
PubMed ID |
Peptide |
Isolation Method |
Antibody |
Mass Spectrometer |
LC System |
iRT Peptides |
Acquisition Mode |
Fragmentation Method |
Gradient |
Gradient Length |
Flow Rate |
Replicate Number |
| ID |
SampleID |
RawFileName |
Organism |
Process |
Tissue_Type |
Cell_Type |
Culture_Conditions |
Disease_State |
Comments |
MHCClass |
MHCAllele |
PubMed_ID |
Peptide |
Isolation_Method |
Antibody |
Mass_Spectrometer |
LC_System |
iRT_Peptides |
Acquisition_Mode |
Fragmentation_Method |
Gradient |
Gradient_Length |
Flow_Rate |
Replicate_Number |
| SYSMHC00007 |
SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D |
SYSMHC00007_Seq44779_QE2.raw |
Human |
In vitro |
Brain |
Lnt-229 |
adherent treated with Decitabine |
Brain tumor |
Glioblastoma-cultured cells |
class I |
HLA-A03:01,HLA-B35:01,HLA-C04:01 |
27412690 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive Plus |
UltiMate 3000 RSLC |
no |
DDA |
HCD |
5-28% of 100% acetonitrile with 0.1% Formic acid |
120 |
15nl/min |
1 |
| SYSMHC00007 |
SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D |
SYSMHC00007_Seq44772_QE2.raw |
Human |
In vitro |
Brain |
Lnt-229 |
adherent treated with Decitabine |
Brain tumor |
Glioblastoma-cultured cells |
class I |
HLA-A03:01,HLA-B35:01,HLA-C04:01 |
27412690 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive Plus |
UltiMate 3000 RSLC |
no |
DDA |
HCD |
5-28% of 100% acetonitrile with 0.1% Formic acid |
120 |
15nl/min |
2 |
| SYSMHC00007 |
SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D |
SYSMHC00007_Seq44773_QE2.raw |
Human |
In vitro |
Brain |
Lnt-229 |
adherent treated with Decitabine |
Brain tumor |
Glioblastoma-cultured cells |
class I |
HLA-A03:01,HLA-B35:01,HLA-C04:01 |
27412690 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive Plus |
UltiMate 3000 RSLC |
no |
DDA |
HCD |
5-28% of 100% acetonitrile with 0.1% Formic acid |
120 |
15nl/min |
3 |